Form 4: Alkermes Executive Sells Shares Under 10b5-1 Trading Plan

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, sold 14,349 ordinary shares at a weighted average price of $30.7722, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, an executive at Alkermes plc, sold 14,349 ordinary shares of the company.
• The sale occurred on December 4, 2024.
• The shares were sold at a weighted average price of $30.7722.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 14, 2023.
• The shares were sold in multiple transactions with prices ranging from $30.50 to $31.00.
• Following the transaction, Hopkinson still beneficially owns 68,951 ordinary shares.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an executive share sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

Executive share sales are a common occurrence and are often part of pre-planned trading strategies. The use of a 10b5-1 plan allows insiders to sell shares without being accused of trading on non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to manage their personal finances and avoid accusations of insider trading.
• Similar sales by executives at comparable biotech companies like Biogen or Vertex are often disclosed through SEC filings.

Stakeholder Impact

• The share sale by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Alkermes, insider trading, Form 4, share sale, 10b5-1 plan, executive, ALKS